Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BETTER Trial in Early Stage TNBC
NCT07610525Phase 2Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab, carboplatin and Paclitaxel Micelles for Injection in triple-negative breast cancer (TNBC) (4 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events at 1 year. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07610525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07610525.